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ABSTRACT
Overexpression of c-Myc is associated with worse outcomes in endometrial 
cancer, indicating that c-Myc may be a promising target for endometrial cancer 
therapy. A novel small molecule, JQ1, has been shown to block BRD4 resulting in 
inhibition of c-Myc expression and tumor growth. Thus, we investigated whether JQ1 
can inhibit endometrial cancer growth in cell culture and xenograft models. In PTEN-
positive endometrial cancer cells, JQ1 significantly suppressed cell proliferation via 
induction of G1 phase arrest and apoptosis in a dose-dependent manner, accompanied 
by a sharp decline in cyclin D1 and CDK4 protein expression. However, PTEN-negative 
endometrial cancer cells exhibited intrinsic resistance to JQ1, despite significant c-Myc 
inhibition. Moreover, we found that PTEN and its downstream PI3K/AKT signaling 
targets were modulated by JQ1, as evidenced by microarray analysis. Silencing of 
PTEN in PTEN-positive endometrial cancer cells resulted in resistance to JQ1, while 
upregulation of PTEN in PTEN-negative endometrial cancer cells increased sensitivity 
to JQ1. In xenografts models of PTEN-positive and PTEN-knock-in endometrial cancer, 
JQ1 significantly upregulated the expression of PTEN, blocked the PI3K/AKT signaling 
pathway and suppressed tumor growth. These effects were attenuated in PTEN-
negative and PTEN-knockdown xenograft models. Thus, JQ1 resistance appears to 
be highly associated with the status of PTEN expression in endometrial cancer. Our 
findings suggest that targeting BRD4 using JQ1 might serve as a novel therapeutic 
strategy in PTEN-positive endometrial cancers.
INTRODUCTION
Endometrial cancer is one of the most common 
gynecological malignancies worldwide [1]. In the United 
States, both the incidence and mortality from endometrial 
cancer continues to rise, with an estimated 60050 new 
cases and 10470 deaths predicted in 2016 [2]. Obesity, 
diabetes and unopposed estrogen are well known risk 
factors for the development of endometrial cancer [3, 4]. 
Though outcomes in early-stage endometrial cancer 
are promising, the management of advanced stage and 
recurrent endometrial cancer remains challenging. 
Novel adjuvant therapies are needed for this subset of 
endometrial cancer [5]. 
c-Myc is a member of the Primary Response Genes 
(PRGs) that responds to the activation of Polymerase II 
[6]. c-Myc targets genes are responsible for encoding 
translational factors, nucleolar assembly components and 
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ribosomal proteins integral to extracellular and intracellular 
signaling for cell growth, tissue regeneration and remodeling. 
In normal cells and cancer cells, c-Myc has been shown to 
manipulate cell proliferation, differentiation, apoptosis, cell 
cycle progression, adhesion, migration, angiogenesis and 
even metabolism through control on the transcription of 
its target genes [6–9]. Ectopic c-Myc expression in normal 
cells, particularly lymphocytes, results in the activation 
of checkpoints, such as p53, Arf or BimL, which cause 
apoptosis and/or cell cycle arrest [6]. Furthermore, enforced 
c-Myc expression in transgenic mice frequently results in 
hyperproliferation associated with reduced apoptosis in the 
target tissue [8, 10]. Knockdown of c-Myc in cancer cells 
in vitro uniformly reduces cell proliferation and in some 
instances, induces apoptosis and cell cycle arrest. In c-Myc 
transgenic mouse models, blocking ectopic c-Myc expression 
inhibits the growth of established tumors, suggesting that it is 
involved in tumor maintenance [11, 12].
There is accruing evidence that aberrant activity 
of c-Myc occurs in approximately 30% of human 
cancers, which results in enhanced tumor initiation and 
progression and correlates with advanced stage cancers, 
poor cellular differentiation, local and distant metastases 
and poorer prognosis [10, 13]. Overexpression of c-Myc 
is observed in 30–50% of patients with endometrial 
cancer and is associated with advanced stage, higher 
grade, distant metastasis and worse prognosis [14, 15]. 
Overexpression of c-Myc has been shown to cause 
increased cell proliferation, cell cycle progression and 
inhibition of apoptosis in endometrial cancer [16]. 
Moreover, endometrial cells transfected with c-Myc 
demonstrate altered morphology, focus formation, 
anchorage-independent growth, chromosomal alterations 
and increased tumor formation in athymic mice[17]. 
A recent study showed that SALL4, an epithelial-
mesenchymal transition and drug resistance inducer, 
regulated cell invasion and drug resistance through the 
regulation of c-Myc in endometrial cancer [18]. This 
evidence suggests that c-Myc plays multiple roles in the 
pathogenesis of endometrial cancer and may serve as a 
potential therapeutic target for this disease.
There are currently several strategies for targeting 
c-Myc, including direct silencing of c-Myc by short 
interfere RNA (siRNA), inhibiting the key downstream 
genes of c-Myc and interrupting the dimerization 
between c-Myc and Max [10, 19]. Unfortunately, most of 
these approaches continue to be hampered by technical 
difficulties, pertaining largely to drug delivery and the fact 
that many c-Myc target genes are functionally redundant 
and/or cell type specific [20]. Recently, a small molecule, 
JQ1, was shown to be a potent c-Myc inhibitor. JQ1 was 
preliminarily designed as an inhibitor of bromodomain-
containing proteins (BRDs), which could release 
BRDs from chromatin and abrogate their functions on 
regulating gene transcription [21]. Subsequent studies 
have shown that JQ1 effectively inhibits cell proliferation 
and tumor growth in a number of human malignancies, 
predominantly through inhibition of c-Myc and its 
downstream targets [22–24]. However, there is currently 
no evidence regarding the effect of JQ1 on cell growth in 
endometrial cancer in vitro or in vivo. In the present study, 
we investigated the effects of JQ1 on cell proliferation 
and tumor growth in endometrial cancer. We found that 
JQ1 significantly inhibited proliferation and tumor growth 
in endometrial cancer, with enhanced efficacy in PTEN-
positive cell lines and xenografts. 
RESULTS
JQ1 inhibited cell proliferation in Hec-1a and 
KLE cells
To investigate the effects of JQ1 on cell proliferation 
in endometrial cancer, we first employed the MTT assay 
to identify the cytotoxicity of JQ1 and measure the IC50 
for each of the six endometrial cancer cell lines of interest. 
Cells were treated with JQ1 at varying concentrations for 
72 hours. The MTT assay demonstrated a dose-dependent 
decrease in cell viability following treatment with JQ1 
(Figure 1A). The IC50 values were 75 nM, 530 nM, 
1950 nM, >10000 nM, >10000 nM, and >10000 nM for 
Hec-1a, KLE, ECC-1, Ishikawa, AN3CA, and RL95-2, 
respectively, after 72 hours of JQ1 treatment. Hec-1a and 
KLE cells were much more sensitive to JQ1 treatment than 
the other four cell lines. 
Considering that in vitro colony formation assay, 
measuring clonogenicity, has been shown to be an 
excellent indicator of long-term tumor survival and a 
predictor of the long-term anti-tumor effects of drugs [25], 
we subsequently assessed whether JQ1 treatment affected 
clonogenicity of Hec-1a and KLE cells. We observed 
that clonogenicity of both cell lines were significantly 
reduced after exposure to JQ1 for two weeks (p = 0.009 
and 0.021, respectively, Figure 1B). Together, these 
results demonstrate suppressive effects of JQ1 on cell 
proliferation in Hec-1a and KLE cells.
We previously reported that JQ1 effectively induced 
cell cycle arrest and apoptosis in a dose dependent manner 
in ovarian cancer cells [26]. We also sought to evaluate 
the effect of JQ1 treatment on cell cycle distribution and 
apoptosis in the two JQ1 sensitive endometrial cancer cell 
lines (Hec-1a and KLE). Following 24 hours of treatment 
with JQ1, we found marked increase in G1 phase and 
reduced S phase in a dose-dependent manner in both Hec-
1a and KLE cells compared to controls (p = 0.015 and 
0.032, respectively, Figure 1C). To further investigate the 
mechanisms of JQ1 on cell cycle, we performed a time-
lapse microarray analysis in Hec-1a cells after treatment 
of 100 nM JQ1 at varying time points (0 hour, 6 hours, 12 
hours and 24 hours). We found that JQ1 inhibited RNA 
expression of c-Myc and cell cycle checkpoint related 
genes (Figure 1D). Western blotting was performed to 
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confirm these findings and showed that JQ1 significantly 
inhibited protein expression of cell cycle checkpoints and 
c-Myc expression in Hec-1a and KLE cells after treatment 
JQ1 with 100 nM or higher doses (Figure 1E). 
In order to determine whether the reduction of 
cell viability was related to apoptosis, we next detected 
apoptotic cells by using the Annexin-V and PI double 
staining assay on Cellometer. As shown in Figure 1F, the 
percentage of Hec-1a and KLE cells undergoing apoptosis 
significantly increased in a dose-dependent manner 
after 24 hours of treatment with JQ1 when compared to 
control. Hec-1a cells treated with 100 nM JQ1 were found 
to have increased the apoptotic rate more than two-fold 
compared to control (p = 0.021). KLE cells also underwent 
increased apoptosis at a JQ1 dose of 500 nM (p = 0.009). 
Collectively, our results suggested that JQ1 inhibited cell 
proliferation through induction of G1 phase cell cycle arrest 
and apoptosis in sensitive endometrial cancer cell lines. 
JQ1 inhibited the tumor growth in xenografts
In order to further evaluate the anti-tumor activity of 
JQ1 in vivo, we established a nude mouse model bearing 
Hec-1a cells. Ten days following injection of Hec-1a cells 
into the nude mice, the mice were treated with JQ1 (50 
mg/kg/day, intraperitoneal injection) or placebo for 28 
days. Tumor growth during treatment was monitored using 
calipers every four days. As shown in Figure 2A and 2B, 
JQ1 significantly suppressed tumor growth and reduced 
tumor weight in Hec-1a xenografts compared to control 
mice after 4 weeks of treatment (p < 0.001). In addition, 
JQ1 was shown to inhibit the expression of Ki-67, c-Myc 
and cyclin D1 in tumor tissues by immunohistochemical 
staining (IHC) (Figure 2C and 2D). These results indicate 
that JQ1 inhibits endometrial tumor growth in vivo via 
inhibition of expression of c-Myc and induction of cell 
cycle arrest. 
Figure 1: JQ1 inhibited cell proliferation in endometrial cancer cells. Six endometrial cancer cell lines were cultured for 24 
hours and then treated with JQ1 at indicated doses in 96 well plates for 72 hours. (A) Cell proliferation was assessed by MTT assay. (B) JQ1 
(100 nM) notably suppressed the colon formation in Hec-1a and KLE cells (p = 0.009 and 0.021 respectively). (C) JQ1 induced significant 
G1 phase arrest in Hec-1a and KLE cells after 24 hours of treatment with JQ1 (ranged from 0 nM to 1000 nM, p = 0.015 and 0.032 
respectively). (D) In a time-lapse course, microarray analysis showed that JQ1 (500 nM) notably downregulated the mRNA expression of 
c-Myc, cyclin D1 and CDK4 in Hec-1a cells. (E) Western blotting results indicated that JQ1 inhibited cyclin D, CDK2, CDK4, CDK6 and 
cyclin E expression in a dose dependent manner after 24 hours of treatment. (F) JQ1 induced Annexin V expression in Hec-1a and KLE 
cells after 24 hours of treatment. 
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JQ1 inhibited PI3K/AKT/S6 pathway via 
upregulating PTEN 
Given that PTEN loss is the most common genetic 
abnormality in type I endometrial cancer, we investigate 
if PTEN status was related to the sensitivity to JQ1 in 
endometrial cancer cells. PTEN status was detected by western 
blotting in all six endometrial cancer cell lines. The results 
revealed that PTEN was abundant in the two JQ1 sensitive 
cell lines while extremely low in other cell lines (Figure 
3A). We hypothesized that JQ1 may affect the expression of 
PTEN in these two sensitive cell lines. Microarray analysis 
was performed to test this hypothesis. Our microarray results 
found a dramatic increase in PTEN with a parallel decrease in 
its downstream targets (PI3K, AKT1/2/3, RPS6 and 4EBP1) 
after treatment with JQ1 in the Hec-1a cells (Figure 3B). 
Confirmatory western blot assays showed that there was 
increased PTEN expression and decreased phosphorylation 
of AKT and S6 in both the Hec-1a and KLE cells, following 
24 hours of JQ1 treatment (Figure 3C, 3D and Supplementary 
Figure S1). These findings suggest that the sensitivity to JQ1 
is associated with PTEN function and the PI3K/AKT/S6 
pathway in these endometrial cancer cell lines.
PTEN status affected cellular sensitive to JQ1 
in vitro
To further investigate the underlying mechanisms 
of JQ1 inhibition of cell proliferation in PTEN-positive 
cells, we transfected the specific shRNA-PTEN plasmids 
into Hec-1a and KLE cells. This generated two cell lines 
with stable knockdown of PTEN and accompanying 
upregulation of phosphorylated-AKT (Figure 4A). 
Cell proliferation was then assessed by MTT assay. 
We hypothesized that the inhibition of PTEN protein 
expression would decrease the cellular sensitivity to JQ1 
treatment. In support of our hypothesis, knockdown of 
the PTEN gene in the both cell lines induced significant 
cellular resistance to JQ1 (Figure 4B and 4C) and 
increased the IC50 for both cell lines (75 nM versus 
420 nM for Hec-1a, 530 nM versus 3350 nM for KLE, 
p = 0.008 and 0.011, respectively). We next examined the 
effect of JQ1 on cell cycle disruption in PTEN knockdown 
cells. Similarly, the loss of PTEN in both cell lines 
resulted in loss of the previously identified G1 phase arrest 
induced by JQ1 at dose of 500 uM (p = 0.025 and 0.019, 
respectively, Figure 4D and 4E).
Figure 2: JQ1 suppressed tumor growth in Hec-1a xenografts in nude mice. JQ1 (intraperitoneal, 50 mg/kg/d, 5 days/week X 4 
weeks) notably decreased tumor volume (A) and tumor weight (B) of Hec-1a xenografts in nude mice (p < 0.001). IHC results showed that 
JQ1 downregulated the protein expression of Ki-67, c-Myc and cyclin D1 in the Hec-1a xenografts (p = 0.039, 0.01 and 0.027, respectively) 
(C and D).
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To further address our hypothesis, PTEN-negative 
and JQ1 insensitive cell lines, AN3CA and Ishikawa, 
were transfected with wild-type PTEN. Cell lysates 
were analyzed by western blotting for PTEN expression. 
Transfection of PTEN increased wild-type PTEN 
expression levels with a sharp decrease in phosphorylation 
of AKT in AN3CA and Ishikawa cells (Figure 4F). MTT 
assay was then performed on the wild-type PTEN AN3CA 
and Ishikawa cell lines, and increased sensitivity to JQ1 
treatment was noted compared to the parent AN3CA and 
Ishikawa cell lines (Figure 4G and 4H, IC50 = 4100 nM 
for AN3CA and 2600 nM for Ishikawa, respectively, 
p = 0.006 and 0.013, respectively). Similarly, cell cycle 
analysis showed that JQ1 increased G1 phase arrest 
in wild-type PTEN AN3CA and Ishikawa cell lines 
(Figures 4I and 4J, p = 0.012 and 0.02, respectively) 
as compared to the parent cell lines. Collectively, our 
results demonstrate that the anti-tumor activity of JQ1 in 
endometrial cancer depends on the PTEN functional status 
of the endometrial cancer cells.
The anti-tumor activity of JQ1 depended on 
PTEN status in vivo
To better elucidate the correlation between PTEN 
status and tumor sensitivity to JQ1, we established four 
nude mice models (Balb b/c nude mice) using parental 
Hec-1a cells, Hec-1a cells with PTEN knockdown, 
parental AN3CA cells and AN3CA cells with PTEN 
knock-in. Beginning ten days after cell injection, 
the mice were treated with JQ1 at 50 mg/kg/day for 
four continuous weeks. The mice showed tolerance 
to JQ1 injections and maintained normal activities. 
Consistent with our results in vitro, Hec-1a xenografts 
with knockdown of PTEN showed less response to four 
weeks of JQ1 treatment compared to their parental Hec-
1a xenograft counterparts, resulting in increased tumor 
weight in the PTEN knockdown mice (Figure 5A and 
5B). The analysis of immunostaining staining showed 
that an increase of the protein levels of Ki-67 and 
phosphorylated-AKT was observed in tumor tissues in 
Figure 3: JQ1 increased the expression of PTEN and blocked the PI3K/AKT/S6 pathway. (A) Western blotting results 
showed the status of PTEN expression in six endometrial cancer cell lines. (B) Microarray results indicated that JQ1 increased the mRNA 
of PTEN and inhibited the PI3K/AKT/S6 signals in Hec-1a cells. Q1 significantly increased the protein expression of PTEN and decreased 
phospho-AKT/phospho-S6 expression in Hec-1a (C) and KLE (D) cells after 24 hours of treatment. 
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Hec-1a xenografts with PTEN-knockdown (p = 0.05 and 
0.003, respectively, Figure 5C and 5D). On the contrast, 
the AN3CA xenografts with PTEN knock-in became 
much more sensitive to JQ1 than their parental ones after 
4 weeks of treatment, accompanied by a decrease in tumor 
weights (Figure 5E and 5F), while IHC results showed 
that expression levels of Ki-67 and phosphorylated-AKT 
were decreased in the tumor tissues in AN3CA xenografts 
with PTEN knock-in treated with JQ1 (p = 0.041 and 
0.018, respectively, Figure 5G and 5H). These results 
confirm that JQ1 inhibition of endometrial tumor growth 
dependent is dependent on PTEN function in vivo.
JQ1 inhibited cell proliferation in primary 
cultures of endometrial cancer
Previous studies have demonstrated that assessing 
the sensitivities of drugs in cancer cells in primary 
culture can provide clinically relevant information for 
the optimization of the cancer patient’s treatment [25]. 
Therefore, we further investigated the effects of JQ1 on 
tumor cell growth in primary cultures of endometrial 
cancer patients using the MTT assay. Twenty-eight tissue 
samples were obtained from patients undergoing primary 
surgical staging for endometrial cancer. After 72 hours of 
treatment with JQ1, 17 of 28 individual patient cultures 
responded to treatment with significant growth inhibition 
at doses up to 10 μM. Ten of the 17 sensitive cultures 
exhibited significantly reduced cell proliferation under 
JQ1 treatment, with a range of IC50 values from 22 to 
530 nM (Table 1). The cell cultures with positive PTEN 
expression were significantly more sensitive to JQ1 than 
the PTEN-negative cells (p < 0.001, Table 1, Figure 6A and 
Supplementary Figure S2), consistent with our previous 
findings in established endometrial cancer cell lines. In 
order to determine if the level of PTEN protein expression 
correlated with sensitivity to JQ1 in each primary culture 
case, we detected the expression of PTEN using western 
blotting in the 28 untreated primary cell cultures. The 
results revealed varying levels of PTEN expression in 11 
Figure 4: The sensitivity of JQ1 is dependent on the status of PTEN in endometrial cancer cells. (A) Knockdown PTEN 
expression by a specific shRNA-PTEN significantly reduced the expression of PTEN in the two endometrial cancer cell lines (B and 
C) Hec-1a and KLE cells with PTEN loss became less sensitive to JQ1 (IC50 = 420 nM for Hec-1a and 3350 nM for KLE). (D and E) 
PTEN loss eliminated the G1 phase arrest caused by JQ1 in Hec-1a and KLE cells after 24 hours of treatment (p = 0.025 and p = 0.019 
respectively). Figure D and E represent one of three independent experiments. (F) The protein level of PTEN was notably elevated in 
AN3CA and Ishikawa cell lines with stably transfection of pcDNA3-PTEN plasmids. (G and H) the AN3CA and Ishikawa cells transfected 
by pcDNA3-PTEN significantly increased the sensitivity of JQ1 compared to their parental cells after 72 hours of treatment (p = 0.006 and 
p = 0.013 respectively). (I and J) JQ1 induced significant G1 phase arrest in AN3CA and Ishikawa cells with PTEN overexpression after 24 
hours of treatment (p = 0.012 and p = 0.02 respectively). Figure (I and J) represent one of three independent experiments. 
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primary culture samples and negative PTEN expression in 
the remaining 17 primary culture samples (Table 1, Figure 
6B). Analyzing this data using a linear regression model, 
we find that PTEN-positive cultures responses to JQ1 were 
dependent upon the level of PTEN protein expression (R2 
= 0.3806, p = 0.0432, Figure 6C). Moreover, we detected 
that JQ1 significantly arrested cell cycle at G1 phase and 
inhibited the expression of cyclin D1 and CDK4 in the 
PTEN-positive but not in PTEN-negative primary cultures 
(Figure 6D and 6E).
DISCUSSION
The key to successful targeted molecular therapies 
is the identification of key oncogenes whose effective 
inhibition can induce apoptosis, cell cycle arrest and/
or cellular differentiation in cancer cells. Accumulating 
in vitro and in vivo evidence suggest that c-Myc is an 
excellent target for anti-cancer therapeutics due to its 
involvement in almost every step of tumor initiation 
and progression [10, 13]. Over the last few years, 
several small molecular inhibitors that specifically target 
c-Myc have been developed. Some of these inhibitors 
have demonstrated promise and will be investigated 
in upcoming clinical trials [19, 27, 28]. Of the c-Myc 
inhibitors, JQ1 has shown particular efficacy in inhibiting 
the expression of c-Myc and its downstream genes. 
Furthermore, in a large panel of human cancer cell lines, 
animal models and human primary tumor samples, JQ1 
has been found to increase G1 cell cycle arrest and induce 
apoptosis and cellular senescence [21–24]. JQ1 has also 
been found to have synergistic effects on the inhibition of 
tumor cell proliferation when combined with fulvestrant, 
an estrogen receptor antagonist, in breast cancer [29], 
γ-secretase inhibitors in T cell acute lymphoblastic 
leukemia [30] and histone deacetylase inhibitors in murine 
lymphoma [31]. 
Given that amplification and/or overexpression of 
c-Myc is frequently detected in human endometrial cancer 
and correlates with worse overall prognosis [14], we 
investigated the inhibitory effects of JQ1 in endometrial 
cancer both in vitro and in vivo. Our results show that JQ1 
significantly suppresses cellular proliferation and induces 
G1 phase cell cycle arrest in endometrial cancer cells 
that express PTEN through inhibition of c-Myc and cell 
cycle checkpoints in both PTEN-positive established cell 
lines and primary cultures of human endometrial cancer. 
Moreover, in vivo, JQ1 also significantly reduced tumor 
growth in PTEN-positive Hec-1a and PTEN knock-in 
AN3CA xenografts. Given the potent anti-cancer effects 
and mild toxicities seen in a large body of in vitro and pre-
clinical studies, JQ1 may offer considerable promise in the 
treatment of PTEN-positive endometrial cancer, among 
others [12, 24, 32].
PTEN loss is the most common molecular alteration 
in endometrial cancer due to mutation, deletion and 
promoter hypermethylation [33]. PTEN mutations have 
been identified in up to 83% of endometrioid carcinomas 
and 55% of precancerous lesions [34]. PTEN protein 
has both lipid and protein phosphatase activity with 
each serving different functions including regulation of 
cell cycle, apoptosis, adhesion, invasion and inhibition 
Figure 5: Tumor sensitivity to JQ1 was dependent on PTEN status in vivo. (A) The Hec-1a xenografts with PTEN loss 
presented resistance to JQ1 after 4 weeks of treatment (p = 0.039). (B) PTEN loss in Hec-1a xenografts significantly increased tumor 
weights (p = 0.027) (C and D) IHC results showed that the protein expression of Ki-67 and phospho-AKT were increased in Hec-1a 
xenografts with PTEN-knockdown (p = 0.05 and 0.003, respectively). (E) AN3CA xenografts with PTEN knock-in became much more 
sensitive to JQ1 than their parental ones after 4 weeks of treatment (p = 0.014). (F) The tumor weights were also decreased in AN3CA 
xenografts with PTEN loss (p = 0.036). (G and H) The expression of Ki 67 and p-AKT were decreased in the tumor tissues with abundant 
PTEN in AN3CA xenografts (p = 0.041 and 0.018, respectively).
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of the PI3K/AKT pathway. Knock-out mice rendered 
heterozygous or homozygous for PTEN developed 
endometrial hyperplasia, atypical hyperplasia and 
endometrial carcinoma [35, 36]. Thus, loss of PTEN 
is likely an early event in endometrial tumorigenesis 
and likely initiated in response to known hormonal 
risk factors for endometrial cancer such as obesity and 
insulin resistance. The loss of PTEN or alterations of 
PTEN expression results in aberrant cell growth and 
apoptotic escape. PTEN restoration results in inhibition 
of cell proliferation, G1 phase cell cycle arrest, induction 
of apoptosis and inhibition of telomerase activity [37, 
38]. The loss of PTEN has been implicated in cellular 
resistance to several oncoprotein targeting agents 
including imatinib, EGFR inhibitors, fulvestrant and 
BRAF inhibitors [39, 40]. A recent study reported that 
intrinsic resistance to JQ1 was found in non-small cell 
lung cancer with mutant KRAS and LKB1, while cells 
with only mutant-KRAS still were sensitive to JQ1 [41]. 
Our data finds that PTEN-positive cell lines are highly 
sensitive to JQ1 when compared to PTEN-negative cell 
lines. In addition, data from both microarray and western 
blotting support that JQ1’s anti-tumorigenic effects are 
dependent on PTEN expression. These results suggest 
that PTEN status may serve as a crucial biomarker of 
intrinsic resistance to JQ1 and PTEN expression testing 
will be important in future trials evaluating JQ1 for cancer 
treatment [42]. 
PTEN is a dual-phosphatase that negatively regulates 
AKT activity. Loss of PTEN and activation of the PI3K/
AKT pathway results in resistance to targeted therapies 
with small molecule compounds in some cancers including 
endometrial cancer, as discussed above. Down-regulation 
of PTEN in breast cancer cells results in trastuzumab-
resistance both in vitro and in vivo, but the use of PI3K 
inhibitors, such as LY294002 and Wortmannin, rescues 
PTEN loss-induced trastuzumab resistance [43]. Data 
from clinical trials has demonstrated that breast patients 
with negative PTEN expression have significantly worse 
response to trastuzumab and shorter overall survival 
than those with positive PTEN expression, suggesting 
that PTEN status can be used as a predictive marker for 
trastuzumab treatment in breast cancer [43]. Recent studies 
also support that PTEN down-regulation can be used as a 
biomarker to predict low response to the EGFR inhibitors 
(cetuximab and gefitinib) in colorectal and lung cancer 
Figure 6: PTEN status related to the sensitivity to JQ1 in the primary cultures of endometrial cancer. (A) The primary 
cultures with negative PTEN were insensitive to JQ1 compared with those with positive PTEN expression (p < 0.001). (B) Western blotting 
showed the status of PTEN expression in the primary cultures of endometrial cancer. (C) The sensitivity to JQ1 in PTEN-positive cultures 
was dependent upon the level of PTEN protein expression using a linear regression model (R2 = 0.3806, p = 0.0432). (D and E) JQ1 caused 
notably G1 phase arrest and decreased protein expression of cyclin D1 and CDK4 in Case 7 (PTEN-positive), but not in case 10 (PTEN-
negative), after 24 hours of treatment. 
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[44, 45]. In this study, we downregulated or upregulated 
the expression of PTEN in JQ1-sensitive or resistant cells 
by stable transfection, and found that knockdown of PTEN 
induced significant resistance to JQ1 and knock-in of 
PTEN re-sensitized the cells to JQ1 in vitro and in vivo. 
The effects of PTEN on JQ1-sensitivity are believed to be 
due to inhibition of the PI3K/AKT pathway. Activation of 
PI3K/AKT pathway has been shown to be responsible for 
loss of PTEN function induced drug resistance. Indeed, a 
panel of small molecular drugs targeting PI3K and mTOR 
pathway were proven to be more effective in patients with 
PTEN loss or PTEN mutation [46, 47]. However, a study 
in glioblastoma found that neither hyperactivated AKT 
nor p53/Rb loss has an effect on the cellular sensitivity to 
JQ1 [23], indicating that PTEN status as predictive marker 
may be associated with certain types of cancer (such as 
endometrial cancer) and not others. 
Assessment of chemotherapeutic drug sensitivities 
using primary culture cancer cells provides clinically 
relevant information for the optimization of cancer 
treatment strategies [48]. In a panel of 28 primary cell 
cultures from endometrial cancer patients undergoing 
primary surgery, positive PTEN expression was correlated 
with JQ1 inhibition of cell growth and induction of cell 
cycle arrest. The level of PTEN protein expression in 
untreated cells from primary cultures was associated with 
sensitivity to JQ1. Further analysis found that c-Myc 
protein expression was not associated with sensitivity to 
JQ1 in these cells (data not shown). These results provide 
further support that inhibition of bromodomain and 
extra terminal proteins (BET) may be used as a potential 
therapeutic approach in endometrial cancer patients with 
PTEN expression. As for endometrial cancer patients with 
PTEN loss, combination therapy with PI3K inhibitors 
Table 1: Summary of patients’ information for primary culture 
Case No. Stage Grade Histologic subtype IC50(nM) PTEN status
1 IA 1 Endometrioid 36 positive
2 IB 1 Endometrioid 320 positive
3 IA 1 Endometrioid 775 negative
4 IA 2 Endometrioid 22 positive
5 IB 1 Endometrioid 2600 negative
6 IA 2 Endometrioid 220 positive
7 IA 2 Endometrioid 190 positive
8 IA 1 Endometrioid 2260 negative
9 IA 2 Serous > 10000 negative
10 IB 1 Endometrioid > 10000 negative
11 IA 1 Endometrioid 78 positive
12 IB 1 Endometrioid 139 positive
13 II 1 Endometrioid 650 negative
14 IA 2 Endometrioid > 10000 negative
15 IIIA 3 Endometrioid 3300 negative
16 IB 1 Endometrioid 615 positive
17 IA 1 Endometrioid 1850 negative
18 IA 1 Endometrioid 86 positive
19 IIIC1 2 Endometrioid 950 negative
20 IIIC1 3 Endometrioid 120 negative
21 IA 1 Endometrioid 830 positive
22 IIIC1 3 Endometrioid 835 negative
23 IIIA 1 Endometrioid 1850 negative
24 IIIC1 3 Undifferentiated > 10000 negative
25 IA 1 Endometrioid 530 negative
26 IIIC1 2 Serous 1600 positive
27 IVB 3 Undifferentiated 500 negative
28 IIIC2 3 Undifferentiated > 10000 negative
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(to overcome the PTEN loss mediated resistance) for 
bromodomain inhibitors, including JQ1, should be 
explored. 
In summary, targeting c-Myc via JQ1 was found 
to have promising anti-tumorigenic activity in PTEN-
positive endometrial cancer cell lines, primary cultures 
and xenografts. Our work suggests a causal link between 
JQ1 treatment and the PTEN/PI3K/AKT pathway in 
endometrial cancer in vitro and in vivo. We believe our 
present study establishes a fundamental relationship of 
inhibition of c-Myc by JQ1 to cell proliferation, apoptosis 
and cell cycle arrest in endometrial cancer cells, providing 
a molecular basis for the use of bromodomain inhibitors 
for endometrial cancer treatment. 
MATERIALS AND METHODS
Cancer cell lines and reagents
The cell lines used in this study were ECC-1, 
KLE, RL95-2, Ishikawa, AN3CA, and Hec-1a. For the 
ECC-1 cells, RPMI 1640 medium with 5% fetal bovine 
serum (FBS) was used. For the KLE and RL95-2 cells, 
DMEM/F12 with 10% FBS was used. For the Ishikawa 
and AN3CA cell s, MEM with 5% FBS was used. For the 
Hec-1a cells, McCoy’s 5A with 10% FBS was used. All 
cells were purchased from ATCC (American type culture 
collection, USA) and cultured at 37°C in a humidified 
incubator containing 5% CO2. All the reagents used in 
this study were purchased from Sigma-Aldrich (St. Louis, 
MO), unless otherwise stated. JQ1 was kindly gifted by 
Dr. James E. Brander (Harvard Medical School, MA). All 
the primary antibodies for phosphorylated-S6, pan-S6, 
phosphorylated-AKT, pan-AKT, cyclin D1, CDK6, CDK4 
and Ki-67 were obtained from Cell Signaling Technology 
(Danvers, MA, USA). Enhanced chemiluminescence 
(ECL) detection reagents were purchased from GE Health 
care (Piscataway, NJ).
Western blotting
Total protein was extracted from tumor cells or 
tissues using RIPA buffer (Thermo Fisher, MA) and 
quantified by BCA assay (Thermo Fisher). Equal amounts 
of total protein (50 μg) were separated by 12% SDS-
PAGE, transferred onto PVDF membrane, blocked in 5% 
non-fat milk for 1 hour and incubated with the primary 
antibodies (1:1000 diluted) overnight at 4°C. On the 
second day, the membrane was incubated with appropriate 
secondary antibodies for 2 hours at room temperature and 
then the specific bands were developed using ECL buffer. 
The results were quantified using the Alpha Innotech 
Imaging System (San Leandro, CA). β-actin (Sigma-
Aldrich, 1:2000 diluted) was used as the endogenous 
control. The experiments were performed in triplicate and 
repeated at least three times.
Tissue samples collection and primary cell 
culture
Twenty-eight consecutive pathologically diagnosed 
endometrial cancer samples were collected from UNC 
Hospital (Chapel Hill, NC, USA) and the First Affiliated 
Hospital of Zhengzhou University (Zhengzhou, China) 
from September 2012 to December 2014. All patients 
provided written consents and approval was obtained 
from the respective Institutional Review Board (IRB) 
committees. Tumors were staged and graded according 
to the criteria of the International Federation of 
Obstetrics and Gynecology (FIGO) 2009. All patient 
and corresponding tumor information is summarized in 
Table 1. For the primary culture, the fresh tumor tissues 
were immediately washed three times with Hank’s 
Buffered Salt Solution (HBSS), gently minced using a 
scalpel, then placed in DMEM/F12 medium containing 
10% FBS. These cells were digested in a mixture of 0.1% 
collagenase IA, 100 U/ml penicillin and streptomycin for 
0.5 to 1 hour at 37°C. After centrifuging twice with PBS 
solution, cells were resuspended and diluted to 1 × 105 
cells/ml with DMEM/F12 medium. Next, 2 × 104 cells/
well were seeded into 96-well plates for MTT assay, and 3 
× 105 cells/well were plated in 6-well plates for cell cycle 
analysis. Cells were incubated overnight before treatment 
with JQ1. Cellular growth curves and cell cycle phase 
distribution were measured after 24 and 72 hours of JQ1 
treatment, respectively.
MTT assay 
The effect of JQ1 on cellular growth was determined 
by MTT assay. Briefly, 4 × 103 cells/well were seeded 
into 96-well plates and incubated overnight. Plates were 
then treated with JQ1 at different concentrations for 72 
hours. Five μl of MTT solution (5 mg/ml) was added to 
each well and incubated for 1 hour. The formazan crystals 
were dissolved in 100 μl of DMSO. The absorbance was 
measured at 570 nm with a microplate reader (Tecan, 
Morrisville, NC). Each experiment was performed in 
triplicate to assess for consistency of results.
Colony formation assay
One hundred cells/well were plated into 6-well 
plates and incubated overnight. The cells were then 
treated with 100 nM of JQ1 on the following day and 
further cultured at 37°C for two weeks. After two weeks, 
the cells were fixed using chilled 10% methanol for 10 
minutes and then stained in 0.5% Gimsa solution for 15 
minutes. The excess staining solution was gently rinsed 
and colonies containing more than 50 cells were counted 
using an optical microscope. Cells were also treated with 
DMSO as the negative control. Colony formation assays 
were performed in duplicate for consistency of results.
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Cell cycle analysis
Cell cycle distribution was measured by the PI 
staining method on Cellometer (Nexcelom, MA). Briefly, 
1.5 × 105 cells/well were seeded into 6-well plates and 
treated with JQ1 for 24 hours. Control cells were treated 
with DMSO. After treatment, cells were fixed in chilled 
90% methanol and stored at -20°C for at least 2 hours. 
Next, the cells were washed with PBS and incubated 
with 50 μl RNase A solution. 50 μl of PI staining solution 
(containing 2 mg/ml PI, 0.1 mg/ml Azide, and 0.05% 
Triton X-100) was added to the cell suspension. The 
final mixture was incubated for 15 minutes in the dark 
before being analyzed using the Cellometer. Cell cycle 
analysis was performed by FCS Express 4 software (De 
Novo Software, Los Angeles, CA). All experiments 
were performed in triplicate to assess for consistency of 
response.
Apoptosis assay
Apoptosis was detected using the PI/Annexin V 
staining kit (Thermo Fisher) on Cellometer. Briefly, 1.5 × 
105 cells/well were seeded into 6-well plates and incubated 
overnight. Cells were then treated with different doses of 
JQ1 for 24 hours. Control cells were treated with DMSO. 
The cells were harvested and stained by PI (2 mg/ml) and 
Annexin V (100 μg/ml, Biolegend, CA) for 15 minutes in 
the dark. The apoptotic cells were detected by Cellometer 
and the results were analyzed by the FCS Express 4 
software. All experiments were performed in triplicate to 
assess for consistency of response.
Establishment of the stably transfected cell lines
The pcDNA3-PTEN and shRNA-PTEN plasmids 
were obtained from Addgene (plasmid 10759 and 10669, 
Cambridge, MA). The pcDNA3-PTEN or shRNA-PTEN 
plasmids were transfected into AN3CA or Hec-1a cells 
using FuGENE HD following manufacturer instructions 
(Roche, Mannheim, Germany). Cells were then 
maintained with G418 (500 μg/ml, Gibco, CA) to select 
the stably transfected clones. The cells transfected with 
empty plasmids were set as the negative control. PTEN 
protein expression was determined using western blotting.
Tumor xenografts growth assay
Six-week-old female mice with severe combined 
immunodeficiency were used for this assay. All mice were 
handled according to protocols approved by the ethics 
committee of Zhengzhou University. In brief, 1 × 106 cells 
were injected subcutaneously into the right flank of mice. 
Ten days after injection, JQ1 (IP, 50 mg/kg/d) or DMSO 
was administered to different groups of mice. The tumor 
size was measured using calipers every four days. The 
tumor volume was calculated using the formula (length 
× width2)/2. All the mice were sacrificed after four weeks 
of JQ1 treatment and the tumor tissues were collected for 
further analysis.
To study the anti-tumor functions of JQ1, two 
groups of mice were used (n = 4 in each group): Hec-
1a+DMSO and Hec-1a+JQ1. To confirm the effects of 
PTEN on JQ1 resistance, another four groups of mice 
were used (n = 4 in each group): Hec-1a+JQ1, Hec-1a-
PTENloss+JQ1, AN3CA+JQ1 and AN3CA-PTENgain +JQ1. 
Microarray analysis
Microarray studies were performed as previously 
described [49]. Briefly, 1.5 × 105 Hec-1a cells/well were 
plated in 6-well plates and treated with JQ1 (500 nM) for 
0, 6, 12 and 24 hours. Total RNA was extracted using the 
RNAeasy Kit (Qiagen, Hilden, Germany). Hybridization 
was performed using a UNC-customized microarray 
from Agilent Technologies (Santa Clara, CA). The results 
were analyzed with GenePix Pro 4.1 and uploaded onto 
the Microarray Database of UNC at Chapel Hill (https://
genome.unc.edu/). These assay was performed in duplicate 
for consistency of results.
Immunohistochemical staining (IHC) 
Tumor tissues from mice were formalin-fixed 
and paraffin-embedded. After rehydration and antigen 
retrieval, the slides (thickness = 4 μm) were incubated 
with primary antibodies: anti-Ki-67 (1:300), anti-c-Myc 
(1:100), anti-cyclin D1 (1:50), anti-PTEN (1:100) and 
anti-p-AKT (1:50). The staining was visualized using 
DAB (Invitrogen, CA). The slides were scored by two 
pathologists. 
Statistical analysis
Results were compared by Student’s t test and 
data were expressed as mean ± S.E. χ2 test was used for 
the analysis of 2 × 2 tables. Statistical significance was 
defined to be p < 0.05.
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